Search results
How Drug Companies Stifle Competition With ‘Product Hopping’
Forbes· 23 hours agoActavis had spent that sum to acquire Forest and its portfolio of pharmaceutical products. Forest...
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like...
Benzinga· 7 hours agoRoundhill Investments launched a new exchange-traded fund (ETF) Tuesday. What Happened: The...
If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today
Motley Fool via Yahoo Finance· 13 hours agoThe big pharma company sells Mounjaro and Zepbound, both prescribed for weight loss, and demand has...
Congress to evaluate how to lower prescription prices by increasing competition
WFXT via Yahoo News· 6 hours agoThey say big pharma has a limited period to sell a new drug before a generic version of it can hit...
Pharmaceutical giant Incyte will move into two of Wilmington's most iconic buildings
Delaware Online | The News Journal via Yahoo Finance· 9 hours agos Stine-Haskell Center near Newark. There, a core team of former DuPont scientists re-founded Incyte...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 6 hours agoEupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging ...
Mira Pharmaceuticals progresses Ketamir-2 preclinical trials By Investing.com
Investing.com· 1 day agoMIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), a pre-clinical-stage pharmaceutical company, announced...
Medical company plans $225M investment, 274 jobs in West Chester Twp.
WCPO Cincinnati· 8 hours agoNational ...AstraZeneca facility on Trade Port Drive in 2023. The company announced earlier this year it planned to redevelop the site, investing at least $225 million...though ...
Lots of drug companies talk about putting patients first — but this one actually did
KPBS San Diego· 7 days agoIn April, the co-CEOs of Amylyx Pharmaceuticals fulfilled a promise they made years earlier to...
GSK's Potential Blockbuster Asthma Drug Shows Promise in Latest Trial — 2nd Update
Morningstar· 16 hours agoGSK's experimental drug for asthma met its goals in the latest trial, moving a treatment with potential annual peak sales of more than 3 billion pounds ($3.81 billion) closer ...